SEC Form 4 · accession 0001415889-19-000113
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil S. Belloff
Officer — GENERAL COUNSEL/CORPORATE SECR
Period of report
Jan 30, 2019
Accepted (ET)
Jan 31, 2019 · 7:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2,F1 | $11.53 | Jan 30, 2019 | A | 50,000 | A | — | Jan 30, 2029 | Common Stock | 50,000 | 50,000 | D |
| Restricted Stock UnitsF5,F3,F4 | — | Jan 30, 2019 | A | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter.
- F2The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
- F3Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F4The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date.
- F5The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.